06/08/2025
Ultromics has raised $55M in Series C funding led by L&G – Asset Management, Allegis Capital and Lightrock, with support from Oxford Science Enterprises, GV (Google Ventures) and major U.S. health systems.
Ultromics’ FDA-cleared, Medicare-reimbursed EchoGo® platform uses to detect elusive heart conditions like HFpEF and cardiac amyloidosis from standard echocardiograms, improving early diagnosis without new hardware or workflow disruption.
EchoGo® has a**lyzed over 430,000 scans, boosting HFpEF detection by 73.6% in studies. With growing adoption at top hospitals, Ultromics aims to make AI diagnostics standard in cardiac care.
“Hospitals have the data, but lacked tools to extract subtle diagnostic signals. With AI, we help clinicians spot high-risk patients earlier so they can intervene sooner,” said Ross Upton, PhD, CEO and Founder of Ultromics. “We built our platform to fit seamlessly into clinical workflows, and this funding lets us scale across the U.S. as health systems tackle the heart failure crisis.”
“Ultromics is an early leader in AI-powered cardiac diagnostics, bringing innovative technology to an underserved market,” said Alastair Stewart, Head of Investments at L&G. “This Series C round shows the huge potential for technology to transform how clinicians detect and treat serious heart diseases.”
“Heart failure and cardiac amyloidosis strain healthcare systems and demand scalable, accurate diagnostic solutions,” said Umur Hursever, Partner at Lightrock. “Ultromics’ AI technology is already improving diagnosis and expanding access to care. We’re proud to support their mission and impact.”
“Millions with treatable heart failure are missed due to subtle symptoms and hard-to-read echoes,” said Victor Westerlind, Managing Director at Allegis Capital. “Ultromics closes this gap by using AI to help physicians spot high-risk patients sooner—a breakthrough that will save lives.”
